RecruitingPhase 3NCT05407987

Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

Studying Autosomal recessive sideroblastic anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AHS Cancer Control Alberta
Intervention
Ferric derisomaltose(drug)
Enrollment
82 enrolled
Eligibility
18 years · FEMALE
Timeline
20252026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05407987 on ClinicalTrials.gov

Other trials for Autosomal recessive sideroblastic anemia

Additional recruiting or active studies for the same condition.

See all trials for Autosomal recessive sideroblastic anemia

← Back to all trials